Drugs / Fluticasone/Salmeterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00252863 | Dec 2004 → May 2006 | asthma | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-03-19 | AstraZeneca | Results Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes astrazeneca.com ↗
Overall, budesonide/formoterol reduced the annual rate of moderate to severe exacerbations by 26% compared to fluticasone/salmeterol (0.80 vs. 1.09 /patient-year; p<0.0001). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-03-19 | AstraZeneca | Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluticasone/Salmeterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00252863 ↗ |
| Route | Inhaled | “Fluticasone/Salmeterol Discus 250/50 µg” NCT00252863 ↗ |